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ABSTRACT: 16 
 17 
Spin-freezing as alternative freezing approach was evaluated as part of an innovative 18 
continuous pharmaceutical freeze-drying concept for unit doses. The aim of this paper 19 
was to compare the sublimation rate of spin-frozen vials versus traditionally frozen vials 20 
in a batch freeze-dryer, and its impact on total drying time. 21 
Five different formulations, each having a different dry cake resistance, were tested.  22 
 23 
After freezing, the traditionally frozen vials were placed on the shelves while the spin-24 
frozen vials were placed in aluminium vial holders providing radial energy supply during 25 
drying. Different primary drying conditions and chamber pressures were evaluated.  26 
After two hours of primary drying, the amount of sublimed ice was determined in each 27 
vial. Each formulation was monitored in-line using NIR spectroscopy during drying to 28 
determine the sublimation endpoint and the influence of drying conditions upon total 29 
drying time. 30 
 31 
For all tested formulations and applied freeze-drying conditions, there was a significant 32 
higher sublimation rate in the spin-frozen vials. This can be explained by the larger 33 
product surface and the lower importance of product resistance because of the much 34 
thinner product layers in the spin frozen vials. The in-line NIR measurements allowed 35 
evaluating the influence of applied drying conditions on the drying trajectories.  36 
 37 
Keywords: freeze-drying, continuous freeze drying, spin freezing, NIR spectroscopy 38 
 39 
 40 
1. INTRODUCTION 41 
  42 
Lyophilisation or freeze-drying is a low temperature drying process, based on 43 
principles of mass and heat transfer, employed to convert solutions of (heat) labile 44 
materials into solids having sufficient stability for distribution and storage. 45 
Pharmaceutical freeze-drying is a batch process, although the handling equipment 46 
before (filling) and after (capping and packaging) freeze-drying is continuously 47 
operated. A typical pharmaceutical freeze-dryer consists of a drying chamber in which 48 
the vials (pharmaceutical unit doses typically containing 0.5-10 ml of a solution) are 49 
placed on temperature controlled shelves (see Figure 1). The shelf temperature is set 50 
and controlled during processing using a thermal fluid flowing through the shelves. A  51 
lyophilisation cycle consists of three consecutive steps: freezing,  primary drying and 52 
secondary drying (Pikal, 2002; Wang, 2000; Khairnar et al, 2013). During freezing, the 53 
shelves are chilled and most of the water in the formulation crystallizes to ice, thus 54 
concentrating the solutes between the ice crystals. Some of the solutes crystallize, 55 
while those that do not are transformed into a rigid glass when the product temperature 56 
drops below the glass transition temperature (Tg') of the amorphous matrix (Kasper, 57 
2011). At the end of the freezing step a frozen plug is formed at the bottom of the vial. 58 
Primary drying is induced by reducing the chamber pressure and increasing the shelf 59 
temperature (to supply energy for sublimation), hence removing the ice crystals by 60 
sublimation. The ice-vapor interface in the vials, i.e., the sublimation front, moves 61 
slowly downward as the sublimation process progresses. During primary drying, the 62 
product temperature is kept below the collapse temperature (Tc), hence ensuring a 63 
solid and rigid cake after lyophilisation. Freeze-drying ends with a secondary drying 64 
step under deep vacuum where most of the unfrozen water (i.e., water dissolved in the 65 
solid amorphous phase) is removed by desorption (Pikal, 2002). Since no crystalline 66 
water (ice) is present during secondary drying, it is performed at a higher shelf 67 
temperature without the risk of thawing of the product. 68 
 69 
 70 
Figure 1: Lab-scale freeze drying chamber with four temperature controlled shelves 71 
 72 
The drying chamber is connected to the condenser via a duct. During primary and 73 
secondary drying, the sublimated ice and removed water is captured on the condenser, 74 
where the temperature and vapor pressure are kept lower than in the drying chamber.  75 
 76 
Freeze drying performed via this batch-wise concept has several important 77 
disadvantages: 78 
 79 
1. The freezing step is uncontrolled at the vial level, which has significant impact on 80 
the consecutive drying steps. Freezing initially involves the cooling of all aqueous 81 
solutions (vials) in the freeze-dryer until ice nucleation occurs. The solutions generally 82 
do not freeze spontaneously at their equilibrium freezing point (0°C). The retention of 83 
the liquid state below the equilibrium freezing point of the solution is termed as 84 
'supercooling'. Ice nucleation is in general a stochastic event, hence inducing vial-to-85 
vial variation based on the degree of supercooling: a higher degree of supercooling 86 
increases the rate of ice nucleation and the effective rate of freezing, yielding a high 87 
number of small ice crystals. In contrast, at a lower degree of supercooling, a lower 88 
number of large ice crystals is formed. As a consequence, the size of the ice crystals 89 
differs from vial to vial which affects the sublimation rate (i.e., required drying time) 90 
during primary drying. E.g., as a high degree of supercooling produces small ice 91 
crystals, smaller pores are formed in the dried layer during sublimation, which offers a 92 
higher resistance to water vapor transport during primary drying. Smaller pores will 93 
also decrease the ease of reconstitution of the freeze dried product. (Kasper and 94 
Friess, 2011). 95 
 96 
2. Uneven heat transfer in the freeze-drying chamber. This results in differences in 97 
energy input in vials that are placed at different locations on the freeze-dryer shelves. 98 
E.g., vials on the edge of the shelves are exposed to more heat radiation transfer from 99 
the warmer surroundings (i.e., door and walls of the freeze-dryer) compared to the vials 100 
in the middle of the shelves. This vial-to-vial variability in heat transfer results in 101 
significant vial-to-vial difference towards product temperature (danger for collapse!) 102 
and drying rate (see Figure 2) (Kauppinnen et al., 2013). 103 
 104 
Figure 2: temperature differences of vials depending on their location on the freeze-105 
dryer shelf (Kauppinnen et al., 2013) 106 
 107 
Both, disadvantages 1 and 2 result in different freeze-drying process conditions in each 108 
vial, which might lead to uncontrolled vial-to-vial and batch-to-batch end product 109 
variability (e.g., differences in residual moisture content, API state and stability). 110 
However, quality is only assessed on a very small fraction of the vials in the freeze-111 
dried batch prior to batch release, which might not represent the entire batch. Such a 112 
manufacturing approach is in conflict with the recent Quality-by-Design and Process 113 
Analytical Technology guidelines from the regulatory authorities (FDA and EMA), 114 
stating that quality should be built into and guaranteed in each dosage form (i.e., in 115 
each released vial) (ICH Q8(R2), 2009).  116 
 117 
3. It is a slow, and hence time-consuming and expensive process. The whole cycle 118 
may last 1 to 7 days (and even more) depending on the product properties and the 119 
dimensions of the vials (Tang and Pikal, 2004). 120 
 121 
4. It is a batch process. In an industrial environment large numbers (tens of thousands) 122 
of vials are treated per batch, which induces operational risks, such as complicated 123 
handling of vials for loading and unloading of the freeze-dryer. Furthermore, since the 124 
handling equipment before (filling) and after (capping, packaging) freeze drying is 125 
continuously operated by nature, buffer systems are necessary. This increases the risk 126 
of product contamination. 127 
 128 
5. The handling equipment takes up a large area of space, which is very expensive in 129 
terms of capital investment and operational costs because of the high standards of 130 
cleanliness and sterility, which are mandatory in production of biopharmaceuticals 131 
(Baertschi et al., 2011). 132 
 133 
6. A batch freeze-dryer is commonly designed and optimized to process only the 134 
largest applicable amount of vials. Different loadings will require different optimal 135 
process conditions in the freeze-drying chamber and may not be allowed for that 136 
reason, unless separately validated. And, it is possible that the required batch sizes 137 
are smaller which leads to inefficient use of the infrastructure.  138 
 139 
7. The installation is subject to various thermal and pressure conditions. This leads to 140 
thermal inefficiencies and the transient conditions may not be well defined. 141 
  142 
8. The course of the freeze drying process cannot be monitored at the scale of the 143 
individual vial. The product behaviour (at molecular level) in each vial during freeze-144 
drying is unknown (Kauppinnen et al., 2013). 145 
 146 
9. Up-scaling from lab-scale freeze-dryers to pilot-scale and industrial-scale freeze-147 
dryers requires extensive re-optimisation and re-validation of the process (Rambhatla 148 
et al., 2004; Trappler, 2004). 149 
 150 
To overcome these disadvantages, a continuous freeze-drying concept  is presented 151 
and evaluated (Corver, 2013). 152 
 153 
 154 
2. CONTINUOUS PHARMACEUTICAL FREEZE-DRYING OF UNIT 155 
DOSES  156 
 157 
The continuous freeze-drying concept starts with a continuous freezing step where the 158 
vials, filled with the liquid formulation, are rotated rapidly along their longitudinal axis 159 
(i.e., spin-freezing, see Figure 3). The cooling and freezing of the solution is achieved 160 
by using a flow of sterile gas with a controllable temperature around the rotating vial. 161 
Consequently, the resulting frozen product will be spread over a larger (i.e., entire) vial 162 
surface compared to traditional freeze-drying. The remainder of the cooling process in 163 
order to establish the desired morphological structure of the ingredients and to further 164 
crystallize and solidify the excipients and APIs under the desired process conditions 165 
will be achieved by transferring the vials to a chamber with a controlled temperature 166 
(see Figure 4). 167 
An appropriate load-lock system will be used to transfer the frozen vials between the 168 
continuous freezing and the continuous primary drying unit, both having different 169 
conditions of pressure and temperature (see Figure 4). It is known from the industrial 170 
applications of vacuum deposition that the application of load-locks is required to 171 
separate chambers with different conditions to enable a continuous product flow 172 
(Ramsay, 2003). Two drying chambers (one for primary and one for secondary drying 173 
- the latter not shown in figure 4) will be used. In each drying chamber, an endless belt 174 
system with pockets to hold the individual vials will allow the transport of the vials and 175 
the heat transfer to the vials needed for sublimation and desorption, allowing individual 176 
vial energy input regulation. Since the frozen product is spread over the entire vial 177 
surface (resulting in thin product layers), it is important to assure adequate and uniform 178 
energy supply from the pocket to the product shell in a radial manner. This supply of 179 
energy may take place by radiation or conduction. In a conventional freeze-dryer, the 180 
sublimated ice and desorbed water is collected using cryogenic ice condensers. For 181 
this continuous freeze-drying concept, a condenser system will be used allowing to 182 
continuously remove the condensed water. By increasing the surface area of the 183 
product in the vial, and by consequently decreasing the product layer thickness, it is 184 
our estimation (as further experimentally proven) that for some pharmaceutical 185 
compositions the total process time (under optimized process conditions) may be 186 
reduced with a factor 10 to 40, depending of the specific formulation properties and 187 
vial dimensions. Increasing the vial throughput (i.e., scale-up) can be simply done by 188 
adding parallel lines in the continuous freeze-drying technology modules or by using 189 
identical parallel modules. This concept of using parallel lines is often used in 190 
continuous manufacturing technologies of other industries (semiconductor industry, 191 
automotive industry). Hence, scale-up will not require complete re-optimization and re-192 
validation of the process and freeze-drying of exactly the required amount of vials also 193 
becomes possible. 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
Figure 3: spin freezing of a vial 205 
 206 
 207 
Figure 4: continuous freezing system connected to a continuous drying system 208 
3. AIM OF THE PAPER 209 
 210 
The aim of this study is to evaluate spin freezing as part of a continuous pharmaceutical 211 
freeze-drying concept for unit doses. More specifically, the difference in sublimation 212 
 
 
 
 
 
rate between spin frozen vials and traditionally frozen vials in a batch freeze-dryer was 213 
evaluated and its impact on total drying time. 214 
 215 
 216 
4. MATERIALS AND METHODS 217 
 218 
Five different formulations having a different specific dry product resistance were 219 
selected from literature (Kuu et al., 2006; Overcashier et al., 1999) (Table 1).  220 
Trehalose was purchased from Cargill (Germany). Polysorbate 20, sodium chloride, 221 
lactose and mannitol were purchased from Fagron (Belgium). L-histidine and glycine 222 
were purchased from Sigma-Aldrich (United States). 223 
Prior to freeze-drying, 10ml type I glass vials were filled with a specific volume of the 224 
formulation (see section 4.2).  225 
After Freezing (see section 4.1.), all frozen vials were dried in an Amsco FINN-AQUA 226 
GT4 freeze-dryer (GEA, Köln, Germany). 227 
 228 
TABLE 1: Dry product resistance of the different used formulations  (Kuu et al., 2006; 229 
Overcashier et al., 1999) 230 
   Formulation  Rp (cm
2 
mTorr h g-1) 
1  trehalose: 45mg/ml; polysorbate 20: 0.1mg/ml; 5mM Histidine pH 6,0  0.5 
2  lactose: 30mg/ml; sucrose: 3.42mg/ml; glycine: 3.75mg/ml; sodium chloride: 0.58mg/ml  1.067 
3  mannitol: 30mg/ml; sucrose: 3.42mg/ml; glycine: 3.75mg/ml; sodium chloride: 0.58mg/ml  0.3861 
4  lactose: 30mg/ml  1.771 
5  sucrose: 30mg/ml  1.443 
 231 
 232 
4.1 Spin freezing versus traditional freezing 233 
 234 
A specific aim of this study was to experimentally compare the sublimation rate (and 235 
drying time) of spin frozen vials to traditionally frozen vials, and to investigate the 236 
influence of drying process parameters upon sublimation rate for both types of frozen 237 
vials. Mathematical calculations and simulations of the sublimation rate and primary 238 
drying process for the five used model formulations was beyond the scope of this 239 
manuscript, but is extensively described in another submitted manuscript. This study 240 
(being part of a continuous freeze-drying system for unit doses study) aimed at 241 
experimentally exploring and demonstrating the drying differences between spin frozen 242 
and traditionally frozen vials of the five model formulations.  243 
 244 
Prior to each freeze-drying experiment, the mass of the empty and filled vials was 245 
determined to calculate the mass of the filled volume. After each freeze-drying 246 
experiment, the mass of the vial containing the dried product was determined and the 247 
mass of sublimated water could hence be calculated. 248 
 249 
During spin freezing, the vials were rotated (spinned) around their longitudinal axis at 250 
2500 rotations per minute (rpm). Equation 2 suggests that 2500 rpm results in an 251 
equally spread product layer with a maximal layer thickness difference of 10% between 252 
the bottom and the top of the product layer.  253 
 254 
߱ ൌ ට∆௛	ൈଶ௚௥భమൈ௥మమ                                                    (2) 255 
 256 
Where ω is the angular velocity (rad/sec), ∆h the height of the spin frozen product 257 
layer, g the gravitational constant and r1 and r2 the layer thickness at the bottom and 258 
the top respectively.  259 
 260 
The NIR probe interface (see 4.3.) was focused on the middle of the vial, where the 261 
deviation in layer thickness was 0%. When the solution was spread over the 262 
circumferential vial wall during spinning, the vial was submerged in liquid nitrogen or 263 
surrounded by dry ice. After formation of the frozen product layer, the vials were 264 
immediately transferred to -35°C pre-cooled aluminum vial holders in the freeze-dryer, 265 
after which vacuum was introduced and the shelf temperature set point was changed 266 
to 5°C or 40°C. To supply energy for sublimation through the sidewall of the spin frozen 267 
vials, the aluminum vial holders (see Figure 5) were placed on the shelf in the freeze 268 
drier in which the vials were placed, thereby creating direct contact between the 269 
aluminum holder and the vial. The energy of the shelf was hence conducted through 270 
the aluminum vial holders to the spin frozen vials. Due to the high thermal conductivity 271 
of aluminum (205 W.m-1.K-1) and the close contact between the shelf and the vial 272 
holders, the temperature of the shelf and the holders was the same (as experimentally 273 
verified with thermocouples).  274 
 275 
 276 
Figure 5: Aluminum vial holder 277 
 278 
For the traditional frozen vials, the vials were placed vertically in liquid nitrogen or on  279 
dry ice until the solution formed a frozen plug at the bottom of the vial. Afterwards, the 280 
vials were immediately transferred to the freeze-dryer and placed on the at -35°C  pre-281 
cooled shelves. Thereafter, the vacuum was introduced and the shelf temperature set 282 
point was changed to 5°C or 40°C. 283 
 284 
The applied freeze-drying conditions varied according to an experimental design plan 285 
(see 4.2.). When the vacuum was introduced, the primary drying shelf set point 286 
temperature was set (5°C or 40°C) and kept constant till the end of the experiment.  287 
 288 
 289 
4.2 Design of experiments 290 
 291 
The selection of the methodology was done according to ICH Q8(R2) on 292 
pharmaceutical development: design of experiments. A full factorial experimental 293 
design was performed to study the influence of five formulations having different Rp 294 
values (table 1), filling volume, freezing method and rate and drying settings upon the 295 
mass of sublimed water after 2 hours of drying. An overview of these factors and their 296 
studied ranges is given in table 2. This design, consisting of six factors (one factor with 297 
five levels, one factor with three levels and four factors with two levels), resulted in 240 298 
experiments. Three centerpoint experiments were added, leading to 243 experiments 299 
in total. 300 
 301 
TABLE 2: Factors studied in experimental design 302 
Factor  Level 
formulation  1  2  3  4  5 
freezing method  batch  spin 
freezing rate  liquid nitrogen  dry ice 
vial filling volume (ml)   3 (1.2mm)  3.5 (1.5mm)  4 (1.7mm) 
shelf temperature (°C)  5  40 
chamber pressure (µbar)  100     300 
 303 
A second full factorial design (10 experiments, see table 3) was performed to study the 304 
influence of the five formulations and chamber pressure upon total drying time of spin-305 
frozen vials in liquid nitrogen. 306 
The drying endpoint was determined in-line using NIR  spectroscopy. For traditionally 307 
frozen vials (having rather thick product layers, > 0.5 cm), the drying endpoint of 308 
different formulations was for an important part influenced by their dry product 309 
resistance (Rp). For spin frozen formulations having different Rp values, the drying 310 
endpoint was expected to be similar because of the thin product layers. When having 311 
optimal direct contact between the vial and the vial holder (see 4.1.), the chamber 312 
pressure was expected not to influence the sublimation rate. However, this contact in 313 
our experimental setup was not perfect. Therefore, the influence of chamber pressure 314 
upon the total drying time of the spin frozen formulations was also evaluated. The 315 
applied shelf temperature and filling volume were 40°C and 3.5 ml, respectively. An 316 
overview of the design experiments is given in table 3. 317 
 318 
Both designs were developed and analyzed using the Modde 9.1.1.0. software 319 
(Umetrics AB, Umeå, Sweden). The software calculates 95% confidence levels around 320 
the effects in the effect plots. An effect is considered as significant when the confidence 321 
interval around the calculated effect does  not contain zero. 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
TABLE 3: Full factorial design containing two factors (formulation and pressure) and 332 
one response (total drying time) 333 
Exp No  Formulation  Pressure (µbar)  Total drying time (min) 
1  Formulation 1  100  152 
2  Formulation 2  100  158 
3  Formulation 3  100  175 
4  Formulation 4  100  174 
5  Formulation 5  100  153 
6  Formulation 1  300  138 
7  Formulation 2  300  139 
8  Formulation 3  300  133 
9  Formulation 4  300  152 
10  Formulation 5  300  146 
 334 
4.3 NIR equipment 335 
 336 
To determine the endpoint of primary and secondary drying in spin frozen vials, an NIR 337 
probe coupled to a Fourier-Transform Near Infrared (FT NIR) spectrometer (Thermo 338 
Fisher Scientific, Zellik, Belgium, Nicolet Antaris II near-IR analyzer) was implemented 339 
in the freeze-dryer and placed in the vial holder (see Figure 6). 340 
 341 
The diffuse reflectance NIR spectra were collected in a continuous and non-invasive 342 
way during the in-line NIR experiments (see section 5.2). The NIR spectrometer was 343 
equipped with an InGaAS detector, a quartz halogen lamp and a fiber-optic non-344 
contact probe which was brought into the freeze-dryer chamber through a port in the 345 
sidewall.  Spectra were taken from 10000 cm-1 to 4500 cm-1 with a resolution of 8 cm-346 
1 and averaged over 32 scans. Every process minute, a spectrum was recorded. 347 
The NIR probe was positioned through a hole in a vial holder for the spin-frozen vials. 348 
The sidewall of the vial was hence monitored with a spot size of about 28 mm2. The 349 
effective sample size measured by the NIR probe hence consisted of a small part of 350 
the total sample volume (3.5 ml) (see Figure 6).  351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
Figure 6: in-line NIR monitoring experiment setup 369 
4.4 Multivariate data analysis 370 
 371 
Principal Component Analysis (PCA) was applied to analyze the in-line collected NIR 372 
spectra using a multivariate data analysis software package (Simca 13.0.3, Umetrics 373 
AB, Umeå, Sweden). The spectra were preprocessed using Standard Normal Variation 374 
(SNV) and mean centering prior to analysis.  375 
NIR probe 
Aluminum vial holder 
PCA is a multivariate data analysis technique, also widely used for NIR spectroscopic 376 
process monitoring (Massart et al., 1997). PCA produces an orthogonal bilinear data 377 
matrix decomposition, where principal components (PCs) are obtained in a sequential 378 
way to explain maximum variance: 379 
 380 
D = TPT + E = t1p’1 + t2p’2 + … + tQp’Q + E 381 
 382 
where T is the M × Q score matrix, P the N × Q loading matrix, E the M × N model 383 
residual matrix, Q the number of PCs, N the number of collected spectra at M 384 
wavelengths. Each PC consists of two vectors, the score vector t and the loading vector 385 
p. The score vector contains a score value for each spectrum, and this value informs 386 
how the spectrum is related to the other spectra in that particular component. The 387 
loading vector indicates which spectral features in the original spectra are captured by 388 
the component studied. These unique and orthogonal PCs can be very 389 
helpful in deducing the number of different sources of variation present in the data and 390 
the occurrence of groups of related objects. However, these PCs do not necessarily 391 
correspond to the true underlying factors causing the data variation, since each PC is 392 
obtained by maximizing the amount of remaining variance (De Beer et al. , 2008). 393 
 394 
 395 
5. RESULTS AND DISCUSSION 396 
 397 
5.1 Spin freezing versus traditional freezing 398 
 399 
Equation 1 (Kuu et al., 2006; Overcashier et al., 1999), describing the sublimation rate 400 
during primary drying, clearly suggested a higher sublimation rate for spin frozen vials 401 
due to the higher surface area (A) and the thinner product layer (resulting in a less 402 
important Rp parameter) of spin frozen vials compared to traditional frozen vials. 403 
 404 
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 406 
Where dm/dt is the sublimation rate (g/h), A is the surface area of the frozen product 407 
layer (cm2), Rp is the area-normalized dried product resistance (cm2 mTorr h g-1). Pp 408 
is the equilibrium vapor pressure of ice at the temperature of the sublimating ice 409 
(mTorr) and Pc is the chamber pressure (mTorr). In our spin frozen vials, the frozen 410 
product surface area was 6.8 times higher and the dried product resistance is lower 411 
due to the thin layer (1.2-1.7mm, depending on the applied volume in our experiments) 412 
compared to traditional frozen vials (8-10.7mm). 413 
After having performed its experiments, design 1 (see section 4.2) was analysed using 414 
the Modde software. The effect plot in Figure 7 showed the largest effect for the factor 415 
'freezing method (fre)' upon the amount of sublimated water after two hours of drying. 416 
Batch freezing clearly had a negative significant effect upon the response. This 417 
confirmed the hypothesis that spin frozen vials have much higher sublimation rates 418 
compared to traditional frozen vials due to the larger surface area and the thinner 419 
product layer of the spin frozen vials. 420 
Changing the factor 'shelf temperature (temp)' from 5°C to 40°C whilst keeping the 421 
other factors at their center point increased the mass of sublimated water after two 422 
hours by 0.57g (figure 7). Increasing the shelf temperature resulted in a higher energy 423 
supply towards the frozen product and thus a faster sublimation.  424 
The factor 'chamber pressure (pre)' had an effect of 0.41g. Increasing the chamber 425 
pressure meaned that more gas molecules were present in the space between the vial 426 
and the shelf or vial holder. The convective heat transfer became then more efficient, 427 
leading to a faster sublimation (Ganguly et al., 2013).  428 
‘Freezing rate (coo)’ had no significant effect on the mass of sublimated water after 429 
two hours drying, suggesting that both freezing rates (liquid nitrogen versus dry ice) 430 
did not lead to relevant different degrees of supercooling. The higher the degree of 431 
supercooling, the higher the amount of small ice crystals. Small ice crystals have a 432 
large surface area, hence leading to a lower sublimation rate and a faster desorption 433 
compared to a low degree of supercooling which results in larger ice crystals (Kasper 434 
and Friess, 2011). The effect of supercooling during spin freezing will be examined in 435 
further research. It was expected that the spinning may trigger the ice nucleation 436 
leading to similar degrees of supercooling when using different freezing rates, which 437 
could explain the factor 'freezing rate' not being significant in this study.  438 
The effect of 'filling volume (lay)' upon the mass of sublimated water is low (0.23g). 439 
The filling volume was related to the product layer thickness (Table 2) . Since after two 440 
hours of primary drying only the top layer of the frozen product was sublimated in both 441 
the spin frozen vials and the traditional frozen vials, it could be indeed expected that 442 
the factor filling volume is less relevant. The dry product resistance only increased with 443 
higher dry product layer thicknesses. The effect is not non-significant since the product 444 
surface area in spin-frozen (2533mm²) and traditionally frozen (373mm²) vials was 445 
different. For the factor 'formulation (pro)', formulation 1 showed a negative effect. The 446 
slower sublimation rate could be explained by the higher solutes concentration 447 
compared to the other formulations. Formulation 5, containing only sucrose shows a 448 
positive significant effect. It was unclear why this formulation had a faster sublimation 449 
rate compared to the other four formulations, although having the second highest Rp 450 
value.  451 
 452 
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Figure 7: effect plot of the full factorial design containing all the data. Freezing 454 
method (fre), temperature (temp), chamber pressure (pre), formulation (pro), layer 455 
thickness (lay), freezing rate (coo) 456 
 457 
In a next step, this design (design 1) was divided into 5 subdesigns, i.e., one full 458 
factorial design for each formulation, allowing a more detailed analysis of the influence 459 
of the other examined factors upon sublimation rate per formulation. This subdivision 460 
did not require performing new experiments.  Each subdesign was a full factorial design 461 
consisting of one factor with three levels and four factors each with two levels (Table 462 
2), resulting in 48 experiments. 463 
Similar effects could be observed for each formulation (i.e., each subdesign). The 464 
effect plot of the subdesign from formulation 1 is shown in figure 8. An overview of the 465 
effects for the other formulations (i.e., the other sub designs) is given in table 4.  466 
The factor 'freezing method (free)' has in all five designs the largest effect. This 467 
confirmed again that spin freezing resulted in much higher sublimation rates. Chamber 468 
pressure (pre), shelf temperature (temp) and filling volume (lay) had similar positive 469 
effects for all  formulations (see explanation overall design higher).  470 
 471 
 472 
 473 
Figure 8: effect plot off the full factorial design for formulation 1. Freezing method 474 
(fre), temperature (temp),  chamber pressure (pre), layer thickness (lay) 475 
 476 
TABLE 4: overview of the coefficient plots. Freezing method (fre), temperature 477 
(temp),  chamber pressure (pre), layer thickness (lay) 478 
* non-significant effect, + small positive effect, ++ positive effect, +++ large positive 479 
effect, - small negative effect, --- large negative effect, -* small non-significant 480 
negative effect, +* small non-significant positive effect 481 
factor level Formulation 
1 
Formulation 
2 
Formulation 
3 
Formulation 
4 
Formulation 
5 
Free Spin +++ +++ +++ +++ +++ 
 Batch - - - - - - - - - - - - - - - 
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Lay  + + + +* + 
Coo LN2 - -* - +* + 
 Dry ice + +* + -* - 
Pre  + + + + ++ 
Temp  ++ ++ ++ ++ ++ 
 482 
In a final step, the above described 5 subdesigns were further subdivided according to 483 
freezing method, resulting in a total of ten full factorial designs. This subdivision did not 484 
require performing new experiments. Hence, in each subdesign,  corresponding to 1 485 
formulation and a specific freezing method, the influence of layer thickness, freezing 486 
rate, shelf temperature and chamber pressure upon mass of water sublimed after 2 487 
hours drying was studied. 488 
The analysis of the effects of the full factorial designs for formulation 1 for both freezing 489 
methods is shown in figure 9A (spin freezing) and 9B (traditional freezing). An overview 490 
of the effects for the other formulations is given in Table 5. The major difference  491 
between the effect plots for spin frozen vials and traditional frozen vials was the effect 492 
of the chamber pressure. For spin frozen vials, the effect of chamber pressure and 493 
temperature was within the same range: 0.65g and 0.58g sublimated water after two 494 
hours drying, respectively (see Figure 9A). However, chamber pressure was expected 495 
not to be significant for the spin frozen vials when having optimal direct contact 496 
between vial holder and vial. The importance of chamber pressure hence indicated 497 
inadequate contact between vial and vial holder. An increased chamber pressure then 498 
resulted in more gas molecules between the vial and the shelf or vial holder, leading 499 
to more efficient convective heat transfer, resulting in a faster sublimation. 500 
 501 
For traditional frozen vials, the effect of chamber pressure (0.034g) was much smaller 502 
compared to shelf temperature (0.149g) (see Figure 9B), since the product-vial surface 503 
area was much smaller compared to spin frozen vials (373 mm² versus 2533 mm²). 504 
The largest effect for spin frozen vials and traditionally frozen vials is shelf temperature. 505 
The quantitative value of this effect was 0.65g and 0.15g sublimated water, 506 
respectively. The higher quantitative value for spin frozen vials could be explained by 507 
the faster sublimation rate of  spin frozen vials (see higher).    508 
Layer thickness had a positive and significant effect for spin-frozen formulation 1 509 
(0.41g). A similar result could be found for the other four spin frozen formulations. This 510 
result could not be explained as mentioned above. 511 
 512 
 513 
Figure 9A: effect plot for formulation 1 split for freezing method: spin freezing 514 
temperature (temp), pressure (pre), layer thickness (lay), freezing rate (coo) 515 
 516 
The rationale for creating and analysing these subdesigns was to distinguish the 517 
effect of the factors for each formulation independently. This became for example 518 
clear for the shelf temperature and chamber pressure effects. In the overall design, 519 
these effects were 0.13g and 0.08g, respectively . In the subdesigns, after splitting 520 
for formulation and freezing method, the effects of shelf temperature and chamber 521 
pressure were 0.65g and 0.58g for spin frozen vials  but 0.15g and 0.03g for 522 
traditional frozen vials.  523 
 524 
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Figure 9B: effect plot for formulation 1 split for freezing method: traditional batch 525 
freezing. temperature (temp), pressure (pre), layer thickness (lay), freezing rate (coo) 526 
 527 
TABLE 5: overview of the coefficient plots for the split designs. Temperature (temp), 528 
pressure (pre), layer thickness (lay), freezing rate (coo) 529 
 / no effect, + small positive effect, ++ positive effect, +++ large positive effect, - small 530 
negative effect, -* small non-significant negative effect, +* small non-significant 531 
positive effect 532 
Spin 
Factor Level Formulation 
1 
Formulation 
2 
Formulation 
3 
Formulation 
4 
Formulation 
5 
Lay  ++ ++ ++ ++ ++ 
Coo LN2 - -* -* +* +* 
 Dry ice + +* +* -* -* 
Pre  +++ +++ +++ +++ +++ 
Temp  +++ +++ +++ +++ +++ 
 533 
Batch 
Factor Level Formulation 
1 
Formulation 
2 
Formulation 
3 
Formulation 
4 
Formulation 
5 
Lay  +* / +* +* / 
Coo LN - / - / +* 
 Dry Ice + / + / -* 
Pre  + + + +* ++ 
Temp  ++ +++ ++ ++ +++ 
 534 
 535 
 536 
 537 
 538 
 539 
5.2 In-line NIR monitoring of the freeze-drying process. 540 
 541 
Figure 10 shows the PC 1 versus PC 2 scores plot obtained after principal component 542 
analysis (PCA) of the in-line collected NIR spectra of experiment 1 (design 2, see 543 
materials and methods). 544 
During the first seven drying minutes, the vacuum was introduced and the temperature 545 
of the shelves and vial holder increased. This could be seen in the scores plot as the 546 
scores move towards the first cluster (spectra 1-7). From 8 till 57 minutes, ice 547 
sublimation occured but is not visible in the NIR spectra since ice sublimation started 548 
on the top (inner side wall) of the frozen layer while NIR spectra were collected from 549 
the outer sidewall of the vials. The penetration depth of the NIR light was not sufficient 550 
to detect the sublimation at the top of the product. Hence, no spectral changes were 551 
seen between 8 and 57 minutes (figure 11a) and the corresponding scores were 552 
clustered. 553 
Between minute 58 and minute 89, the intensity of the ice peaks around 5000 cm-1 and 554 
6700 cm-1 started lowering and other product signals appeared in the spectrum (figure 555 
11b). This could be explained by the fact that the sublimation front was moving towards 556 
the NIR probe at the outer wall of the vial. Spectral signals from the formulation became 557 
visible because of the decreasing amount of overwhelming ice signals. Spectrum 104 558 
was the endpoint of primary drying since all ice signals had disappeared in this 559 
spectrum (figure 11c). Secondary drying started already after 89 minutes. During 560 
secondary drying the free water band at 5160 cm-1 decreases in intensity (figure 11d) 561 
(Pieters et al., 2012; De Beer et al., 2009). 562 
152 minutes after the start of the process, secondary drying was finished. The spectra 563 
from minute 152 till 209 formed a cluster, indicating that no changes occured anymore 564 
in the product (figure 11e). 565 
 566 
 567 
 568 
Figure 10: PC1 vs PC2 scores plot obtained after PCA on in-line collected NIR spectra of 569 
formulation 1 570 
 571 
 572 
Figure 11a: spectra 8-57  573 
 574 
Wavenumber (cm‐1)
 575 
 576 
Figure 11b: spectra 58-88,  underlying formulation signals that were overwhelmed 577 
by the ice signals appear in the spectrum   578 
 579 
 580 
 581 
Figure 11c: spectrum 104, end of primary drying 582 
 583 
 584 
 585 
Figure 11d: spectra 104-152, water band intensity at 5160 cm-1 is decreasing during 586 
secondary drying (Pieters et al., 2012) 587 
 588 
Wavenumber (cm‐1)
Wavenumber (cm‐1)
Wavenumber (cm‐1)
 589 
Figure 11e: spectra 152-209, end of secondary drying 590 
 591 
This spectral analysis was done for the five formulations at the two different applied 592 
chamber pressure conditions. An overview of these PCA results is given in Table 6.  593 
 594 
TABLE 6: overview of conclusions obtained after analysis of the NIR spectra. 595 
  100µbar  300µbar 
  1° drying endpoint (min)  2° drying endpoint (min)  1° drying endpoint (min)  2° drying endpoint (min) 
Formulatie 1  103  152  80  138 
Formulatie 2  124  158  103  139 
Formulatie 3  134  157  105  133 
Formulatie 4  108  174  103  152 
Formulatie 5  114  153  88  146 
 596 
 597 
The results of the full factorial design analysis is shown in Figure 12. The effect of the 598 
factor chamber pressure upon drying time was negative. When the chamber pressure 599 
increases, the drying time will decrease. When the factor chamber pressure was 600 
changed from its lowest to its highest value whilst the other factors were kept at their 601 
centerpoint, resulted in a shorter drying time of 17 minutes. This result confirmed that 602 
a higher chamber pressure resulted in a shorter drying time. The explanation of this 603 
unexpected effect is given in section 5.1. 604 
Formulation 4 had a positive effect of 25 minutes. This result was contradictory to the 605 
results of section 5.1 where formulation 4 had no significant effect on the response 606 
mass of sublimated water. A possible explanation was the formation of a dense lactose 607 
layer on the top of the dry product layer leading to a higher dry product resistance and 608 
thus a longer drying time (Chen et al., 2008). 609 
 610 
Figure 12: effect plot of the full factorial design for the in-line NIR monitoring 611 
Formulation (for), pressure (pre) 612 
 613 
 614 
6. CONCLUSION AND FUTURE PERSPECTIVES 615 
 616 
Spin freezing as part of a continuous freeze drying concept for unit doses has been 617 
presented and evaluated. The sublimation rate in spin frozen vials is significantly 618 
higher compared to traditionally frozen vials. This can be explained by the larger 619 
product surface, and the lower importance of product resistance because of the much 620 
thinner product layers in the spin frozen vials compared to the traditionally frozen vials. 621 
Both chamber pressure and shelf temperature have a positive effect on the sublimation 622 
rate. For the experimental conditions tested in this study, the effect of chamber 623 
pressure is more important in spin frozen vials compared to traditionally frozen vials. 624 
The reason for this effect is the poor contact between the vial and the vial holder. An 625 
increased chamber pressure then results in more gas molecules between the vial and 626 
the shelf or vial holder, leading to more efficient convective heat transfer, resulting in a 627 
faster sublimation Due to the larger product-vial surface area of the spin frozen vials, 628 
this factor has a large impact on the sublimation rate.  629 
 630 
In-line NIR monitoring of spin frozen vials allowed monitoring the entire drying process 631 
and determining the primary and secondary drying endpoints, and confirmed the effect 632 
of chamber pressure on the total drying time.  633 
 634 
Mathematical modeling and simulation of the drying process for the five used model 635 
formulations, allowing further clarification of the experimental observations, will be 636 
extensively described in a next manuscript. 637 
 638 
 639 
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